Cancer prognostic biomarkers have shown disappointing clinical applicability. The objective of this study was to classify and estimate how study results are overinterpreted and misreported in prognostic factor studies in oncology. This systematic review focused on 17 oncology journals with an impact factor above 7. PubMed was searched for primary clinical studies published in 2015, evaluating prognostic factors. We developed a classification system, focusing on three domains: misleading reporting (selective, incomplete reporting, misreporting), misleading interpretation (unreliable statistical analysis, spin) and misleading extrapolation of the results (claiming irrelevant clinical applicability, ignoring uncertainty). Our search identified 10,844 articles. The 98 studies included investigated a median of two prognostic factors (Q1–Q3, 1–7). The prognostic factors’ effects were selectively and incompletely reported in 35/98 and 24/98 full texts, respectively. Twenty-nine articles used linguistic spin in the form of strong statements. Linguistic spin rejecting non-significant results was found in 34 full-text results and 15 abstract results sections. One in five articles had discussion and/or abstract conclusions that were inconsistent with the study findings. Sixteen reports had discrepancies between their full-text and abstract conclusions. Our study provides evidence of frequent overinterpretation of findings of prognostic factor assessment in high-impact medical oncology journals.
We sought to establish whether continuous positive airway pressure (CPAP) for obstructive sleep apnoea (OSA) in people with type 2 diabetes and diabetic macular oedema (DMO) improved visual acuity.We randomly assigned 131 eligible patients aged 30–85 years from 23 UK centres with significant DMO causing visual impairment (LogMAR letters identified ≥39 and ≤78, score 0.92–0.14) plus severe OSA on screening to either usual ophthalmology care (n=67) or usual ophthalmology care plus CPAP (n=64) for 12 months.Mean age of participants was 64 years, 73% male, mean body mass index 35.0 kg·m−2. Mean 4% oxygen desaturation index was 36 events·h−1. There was no significant difference in the visual acuity at 12 months between the CPAP group and the control group (mean LogMAR 0.33 (95% CI 0.29–0.37)versus0.31 (95% CI 0.27–0.35); p=0.39), and no significant correlation between change in LogMAR and average CPAP use. The median±sd(range) daily CPAP use was 3.33±2.25 (0–7.93) h at 3 months, 3.19±2.54 (0–8.07) h at 6 months and 3.21±2.70 (0–7.98) h at 12 months.CPAP therapy for OSA did not improve visual acuity in people with type 2 diabetes and DMO compared with usual care alone over 12 months.
Introduction: Malignant pleural effusion (MPE) is common and currently in UK there are an estimated 50 000 new cases of MPE per year. Talc pleurodesis remains one of the most popular methods for fluid control. The value of thoracic ultrasound (TUS) imaging, before and after pleurodesis, in improving the quality and efficacy of care for patients with MPE remains unknown. Additionally, biomarkers of successful pleurodesis including measurement of pleural fluid proteins have not been validated in prospective studies. The SIMPLE trial is an appropriately powered, multicentre, randomised controlled trial designed to assess ’by the patient bedside' use of TUS imaging and pleural fluid analysis in improving management of MPE. Methods and analysis: 262 participants with a confirmed MPE requiring intervention will be recruited from hospitals in UK and The Netherlands. Participants will be randomised (1:1) to undergo either chest drain insertion followed by instillation of sterile talc, or medical thoracoscopy and simultaneous poudrage. The allocated procedure will be done while the patient is hospitalised, and within 3 days of randomisation. Following hospital discharge, participants will be followed up at 1, 3 and 12 months. The primary outcome measure is the length of hospital stay during initial hospitalisation. Ethics and dissemination: The trial has received ethical approval from the South Central-Oxford C Research Ethics Committee (Reference number 15/SC/0600). The Trial Steering Committee includes an independent chair and members, and a patient representative. The trial results will be published in a peer-reviewed journal and presented at international conferences. Trial registration number: ISRCTN: NCT16441661
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous inflammatory airways disease. The epithelial-derived ‘alarmin’ IL-33 and its receptor ST2 have been implicated in airway inflammation and infection. We sought to determine whether astegolimab, a selective ST2 IgG2 monoclonal antibody, reduces exacerbations in COPD. Methods: We undertook a single-centre, randomised, double-blinded, placebo-controlled, phase IIa trial in moderate-to-very severe COPD. Participants received astegolimab 490mg (n=42) or placebo (n=39), every 4 weeks over 44 weeks. Primary endpoint was exacerbation rate over 48 weeks with pre-specified subgroup analysis by baseline blood eosinophil count. Secondary endpoints included Saint George’s Respiratory Questionnaire for COPD (SGRQ-C), FEV1, blood and sputum cell counts, and safety and tolerability. Results: The 48-week exacerbation rate in the astegolimab group relative to placebo was 0.78 (0.53 -0 1.14; p=0.195) in the whole group and 0.69 (0.39 - 1.21) and 0.83 (0.49 - 1.40) in subjects below or above the median baseline blood eosinophil count (170 cells/µL). In the astegolimab group versus placebo the mean difference for SGRQ-C and FEV1 was –3.3 (-6.4 to -0.2; p=0.039) and 40ml (-10 to 90; p=0.094), respectively. The differences in geometric mean ratios for blood and sputum eosinophil counts were 0.59 (0.51 - 0.69; p<0.001) and 0.25 (0.19 - 0.33; p<0.001). Incidence of treatment-emergent adverse events was similar between groups. Conclusion: Astegolimab did not reduce 48-week COPD exacerbation rate significantly in the whole group, subgroup analyses suggested more benefit in subjects with lower blood eosinophil counts.